Financial Results for the Fiscal Year Ended March 31, 2014
August 1, 2013
Exchange where listed: TSE

Name of listed company: TERUMO CORPORATION(URL http://www.terumo.com/): 4543: Yutaro Shintaku, President and Representative Director: Masayuki Maruta, General Manager, Corporate Communication Dept.
: +81 / 3 -6742 -8550

Company code number
Representative:
Please address all communications toPhone
Adoption of U.S. accounting standards [Yes/No]: No

1. Consolidated financial highlights for the interim period ended June 2013
(From April 1, 2013 to June 30, 2013)(1) Consolidated financial results(Notes: The amounts shown below ignore values of less than a million yen)

Net sales

Operating income(Millions of yen)Three months ended June, 2013
Three months ended June, 2012
(Notes) Comprehensive income:%

111,090
95,867

June 2013: 27,849million yen (−%)

(Millions of yen)

13,32915,481

15.9
0.2

Ordinary income%

Net income(Millions of yen)

12,94012,981(13.9)(10.9)%(Millions of yen)

8,956
8,159

(0.3)
(23.0)%

9.8(16.5)

June 2012: (6,081)million yen (−%)
Net income per share,
fully diluted

Net income per share
(Yen)

(Yen)

47.17
−
Three months ended June, 2013
42.97−
Three months ended June, 2012
(Note) Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.

(2) Consolidated financial position
Total assets

Net assets(Millions of yen)

Net assets per share

Equity ratio%(Yen)

795,23458.0
461,579
As at June 30, 2013
56.7
437,909771,032
As at March 31, 2013
(Note) Shareholders' equity : June 30, 2013: 461,234 million yen, March 31, 2013: 437,557 million yen.

2,429.13
2,304.42(Millions of yen)

2. Dividends
Cash dividends per share
4th quarter

1st quarter 2nd quarter 3rd quarter

Year ended March 31, 2013
Year ending March 31, 2014
Year ending March 31, 2014 (forecast)

total(Yen)

(Yen)

(Yen)

(Yen)

(Yen)

−
−

22.00

−

22.00

44.00

29.00

−

29.00

58.00

(Note) Revise of dividends forecast : None

3. Consolidated Forecast for the Year Ending March 2014 (From April 1, 2013 to March 31, 2014)
Net sales
Half year ending September, 2013

Year ending March, 2014

Ordinary incomeOperating income

Net income
per share

Net income(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

(Millions of yen)%

222,000
460,000

15.7
14.3

30,00070,0006.4
31.5

28,50067,50017.7
31.4

19,00042,00030.8(10.7)(Yen)

100.06221.201. Forecast for fiscal year ending March, 2014 which was announced on May 9, 2013 has not been revised.
(Assumed exchange rate for fiscal year ending March, 2014: USD1=JPY95, EUR1=JPY123)
2. Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these areforecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results
may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic
conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

4. Financial Statements(1) Consolidated balance sheet
As at March 31, 2013

As at June 30, 2013%

Amount%Amount(Assets)
I Current assets

286,955

37.2%

292,409

Cash and deposits

78,201

79,584

Noteｓ and accounts receivable-trade

95,00896,060Marchandise and finished goods

54,34657,703Work in process

9,265

9,396

Raw material and supplies

21,56822,886

Deferred tax assets

11,258

9,351

Other

18,52818,737

Allowance for doubtful accounts(1,220)36.8%(1,311)II Noncurrent assets

483,77062.8%

502,357

63.2%

1. Property, plant and equipment

144,824

18.8%

149,21118.8%

Buildings and structures

48,966

48,644

Machinery, equipment and vehicles46,366

45,805

Land

21,827

21,910

Lease assets

704

638

Construction in progress

17,79422,707

Other

9,165

9,506

2. Intangible assets

296,63438.5%

307,206

Goodwill

149,322

153,730

Customer-related assets

90,706

93,763

Other

56,604

3. Investments and other assets

42,311

59,712
5.5%

45,938Investment securities

30,30435,141

Deferred tax assets

5,153

3,670

Other

6,852

III Deferred assets
Total assets

38.6%

5.8%

7,126

306

0.0%

467

0.0%

771,032

100.0%

795,234

100.0%

As at March 31, 2013

Amount

As at March 31, 2013%

Amount%(Liabilities)
I

Current liabilities

115,844

Notes and accounts payable-trade37,51536,701

Short-term loans payable

18,04618,018Current portion of long-term loans payable

3,762

3,943

Lease obligations

112,643277

255

Income taxes payable

2,609

4,500

Deferred tax liabilities

3526

Provision for bonuses

4,834

2,520

Provision for directors' bonuses
Notes and accounts payable-facilities
Asset retirement obligations

II

15.0%

109

27

6,624

8,354

420

72

Other

41,611

38,222

Noncurrent liabilities

217,278

Bonds payable

80,00080,000Long-term loans payable

78,71280,092

439

395

Deferred tax liabilities

49,65951,457

Provision for retirement benefits

1,247

1,330

198

66

Lease obligations

Provision for directors' retirement benefits
Asset retirement obligations

28.2%

221,011

14.2%

27.8%

155

156

Other

6,865

7,511

Total liabilities

333,12243.2%

333,654

42.0%

I

54.5%

424,774

53.4%

Shareholders' equity

419,999

Capital stock

38,716

38,716

Capital surplus

52,103

52,103Retained earnings

329,188333,967

Treasury stock
II(9)Accumulated other comprehensive income

17,557

Valuation difference on available-for-sale securities

7,458

Deferred gains or losses on hedges
Foreign currency translation adjustment
III Minority interests

(12)
2.3%

36,46010,651−(8)

10,09925,817

352

4.6%

0.0%

344

0.0%

Total net assets

437,90956.8%

461,57958.0%

Total liabilities, net assets

771,032

100.0%

795,234

100.0%

(2) Consolidated statement of income
For the year ended

For the year ended

June 30, 2012

June 30, 2013%

Amount%AmountI

Net sales

95,867100.0%

111,090100.0%

II

Cost of sales

44,17546.1%

54,09948.7%

Gross profit

51,692

53.9%

56,99051.3%

36,211

37.8%

43,661

39.3%

15,481

16.1%

13,329

12.0%

966

0.8%

1,355

1.2%

12,940

11.6%

268

0.3%

600

0.5%

12,608

11.4%

3,637

3.3%

III Selling, general and administrative expenses
Operating income
IV Non-operating income

V

Interest income

6482

Dividends income

5656

Royalty income

28

23

Foreign exchange profit−577

Equity in earnings of affiliates

33

Other

331

81514

0.5%

144

Non-operating expenses
Interest expenses

263

368

Sales discounts

154

166

Foreign exchange losses
Loss on disposal of inventories
Other2,410−043185

Ordinary income

3,013

3.1%

12,981

13.5%

777

VI Extraordinary income
Gain on sales of noncurrent assets
Gain on transfer of businessSubsidy income

06262

−
875

875

0.9%

−

VII Extraordinary expenses
Loss on disposal of noncurrent assets

81

9

Impairment loss−

557

Directors' retirement benefits−

Income before income taxes
Income taxes-current

3,991

Income taxes-deferred

1,609

Income before minority interests
Minority interests in income
Net income

810.0%

13,776

14.4%

33

2,370
5,600

5.9%

1,266

8,175

8.5%

8,971

8.1%

160.0%

150.0%

8,159

8.5%

8,956

8.1%

(3) Consolidated statement of comprehensive income

I

Income before minority interests

II

Other comprehensive income
Valuation difference on available-for-sale securities
Deferred gains or losses on hedges
Foreign currency translation adjustments
Share of other comprehensive income of associates
accounted for using equity method
Comprehensive income(Millions of yen)
For three months ended

For three months ended

June 30, 2012

June 30, 2013

AmountAmount

8,175

8,971

3,192

(1,016)(1)(8)(13,237)

15,694(1)(14,256)(0)

18,877(6,081)

27,849(6,054)27,857(26)(8)

Attributable to:Shareholders of Terumo Corporation
Minority interests

5. Segment Information[Reportable Segments](1) The First Quarter of Fiscal year ended March 31, 2013

(Millions of yen)
For three months ended
June 30, 2012

GeneralHospitalBusiness

Cardiac &VascularBusiness

Blood
Management
Business

Subtotal

Adjustment

Total

Sales:
Sales to customer

38,182

41,056

16,62895,867−−−−−−−

Sales total

38,182

41,056

16,62895,867−

95,867

Segment income (loss)

5,959

6,859

287

13,1062,374

15,481

Internal sales

Notes:

95,867

1. Segment income is adjusted to be consistent with operating income shown on theconsolidated income statement.
2. Adjustment to segment income (loss), which amounted to 2,374 million yen, is the sumof 1,300 million yen for Inventories and 1,073 million yen for others.

(2) The First Quarter of Fiscal year ended March 31, 2014

(Millions of yen)
For three months ended
June 30, 2013

GeneralHospitalBusinessCardiac &VascularBusiness

Blood
Management
Business

Subtotal

Adjustment

Total

Sales and operating income:Sales to customer

39,44550,125

21,520111,090−−−−−−−

Sales total

39,44550,125

21,520111,090−111,090

Segment income (loss)

4,788

8,696

577

14,062(733)

13,329Internal sales

Notes:

111,090

1. Segment income is adjusted to be consistent with operating income shown on theconsolidated income statement.
2. Adjustment to segment income (loss), which amounted to (733) million yen, is the sumof (257) million yen for Inventories and (476) million yen for others.

(Note) Main products belonging to each business segment

Business segments

Main products

General Hospital business
Disposable medical devices and medical electronics

Syringes, Needles, Blood collection tubes, Solution sets, I.V.catheters,
Infusion pumps, Syringe pumps, etc.

Pharmaceuticals

I.V.solutions, Nutritious food, Prefilled syringes, CAPD systems, etc.

Diabetes care products

Blood glucose monitoring systems

Consumer Healthcare business

Digital Thermometers, Blood pressure monitors, Blood glucose monitors (OTC), etc.

Cardiac and Vascular business
Interventional systemsAngiographic catheters, PTCA balloon catheters, Coronary stents, Neuro interventionalcoils, etc.

Cardiovascular systems

Oxygenerators, Cardio-pulmonary bypass system, Left ventricular assist system, etc.

Vascular grafts

Artificial vascular grafts, Stent grafts

Blood Management business

Blood bags, Automated blood collection system, Therapeutic apheresis system, Cellexpansion system, etc.